Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumab

Clinical Cancer Research

Volumn 16, Issue 16, 2010, Pages 4236-4245

  Kenny, Laura M ^a   Contractor, Kaiyumars B ^a   Hinz, Rainer ^c   Stebbing, Justin ^a   Palmieri, Carlo ^a   Jiang, Jie ^b   Shousha, Sami ^b   Al Nahhas, Adil ^a   Coombes, R Charles ^a   Aboagye, Eric O ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINE C 11; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; TRACER; TRASTUZUMAB; ANTINEOPLASTIC AGENT; CARBON; CHOLINE; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG RETENTION; DRUG UPTAKE; HUMAN; LOADING DRUG DOSE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIOACTIVITY; RECURRENT CANCER; REPRODUCIBILITY; STEADY STATE; TREATMENT OUTCOME; BREAST TUMOR; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; FEMALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SCINTISCANNING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARBON RADIOISOTOPES; CHOLINE; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS;

EID: 77955751243     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0468     Document Type: Article

References (41)

1. 11C-choline PET. J Nucl Med 2000;41:1507-13.
2. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990-5.
3. 11C]choline. J Nucl Med 1997;38:842-7.
4. Kobori O, Kirihara Y, Kosaka N, Hara T. Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: a novel method of preoperative lymph node staging. Cancer 1999;86:1638-48.
5. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999;59:80-4.
6. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 2004;64:4270-6.
7. 11C]choline positron emission tomography in estrogen receptor-positive breast cancer. Clin Cancer Res 2009;15:5503-10.
8. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as firs-tline treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74.
9. Ramirez de Molina A, Gutierrez R, Ramos MA, et al. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 2002;21:4317-22.
10. Liu D, Hutchinson OC, Osman S, Price P, Workman P, Aboagye EO. Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. Br J Cancer 2002;87:783-9.
11. Hernandez-Alcoceba R, Saniger L, Campos J, et al. Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene 1997;15:2289-301.
12. Ramirez de Molina A, Gallego-Ortega D, Sarmentero-Estrada J, et al. Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy. Int J Biochem Cell Biol 2008;40:1753-63.
13. Banez-Coronel M, de Molina AR, Rodriguez-Gonzalez A, et al. Choline kinase á depletion selectively kills tumoral cells. Curr Cancer Drug Targets 2008;8:709-19.
14. Gallego-Ortega D, Ramirez De Molina A, Gutierrez R, et al. Generation and characterization of monoclonal antibodies against choline kinase á and their potential use as diagnostic tools in cancer. Int J Oncol 2006;29:335-40.
15. Lacal JC. Choline kinase: a novel target for antitumor drugs. IDrugs 2001;4:419-26.
16. Coleman R, DeGrado T, Wang S, et al. 9:30-9:45. Preliminary evaluation of F-18 fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging 2000;3:147.
17. Kotzerke J, Prang J, Neumaier B, et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000;27:1415-9.
18. Richter JA, Rodriguez M, Rioja J, et al. Dual tracer (11)C-Choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment. Mol Imaging Biol 2010;12:210-7.
19. 18F]fluoro-D- glucose in tumor imaging with positron emission tomography. Mol Imaging Biol 2002;4:267-73.
20. Pieterman RM, Que TH, Elsinga PH, et al. Comparison of (11)C-choline and (18)F-FDG PET in primary diagnosis and staging of patients with thoracic cancer. J Nucl Med 2002;43:167-72.
21. 18F-FDG PET. J Nucl Med 2008;49:1245-8.
22. Roivainen A, Yli-Kerttula T. Whole-body distribution of (11)C-choline and uptake in knee synovitis. Eur J Nucl Med Mol Imaging 2006;33:1372-3.
23. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
24. Wahl R, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving criteria for PET response criteria in solid tumours. J Nucl Med 2009;50 Suppl 1:122-50S.
25. Pegram M, Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol 2000;27:13-9.
26. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92.
27. Leyton J, Smith G, Zhao Y, et al. [18F]fluoromethyl-[1,2-2H4]-choline: a novel radiotracer for imaging choline metabolism in tumors by positron emission tomography. Cancer Res 2009;69:7721-8.
28. 11C]choline. J Labelled Comp Radiopharm 2000;43:195-203.
29. Kenny LM, Vigushin DM, Al-Nahhas A, et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 2005;65:10104-12.
30. Mankoff DA, Shields AF, Graham MM, Link JM, Krohn KA. A graphical analysis method to estimate blood-to-tissue transfer constants for tracers with labeled metabolites. J Nucl Med 1996;37:2049-57.
31. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985;5:584-90.
32. 11C]choline; implications for in vivo imaging with positron emission tomography. Eur J Nucl Med 2000;27:25-32.
33. Cunningham VJ, Jones T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab 1993;13:15-23.
34. Barak AJ, Tuma DJ. Betaine, metabolic by-product or vital methylating agent? Life Sci 1983;32:771-4.
35. Zeisel SH. Dietary choline: biochemistry, physiology, and pharmacology. Annu Rev Nutr 1981;1:95-121.
36. Chen JH, Baek HM, Nalcioglu O, Su MY. Estrogen receptor and breast MR imaging features: a correlation study. J Magn Reson Imaging 2008;27:825-3.
37. 18F]dOC). Nucl Med Biol 2004;31:851-8.
38. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[(18)F] fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007;34:1339-47.
39. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999;40:1771-7.
40. Meisamy S, Bolan PJ, Baker EH, et al. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy - a pilot study at 4 T. Radiology 2004;233:424-31.
41. 1H-MR spectroscopy. Radiology 2009;251:653-62.